CYTK
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Cytokinetics reported positive ACACIA-HCM results presented at ESC Congress 2026 and published in The New England Journal of MedicineAug 28, 2026
- Cytokinetics received UK MHRA marketing authorization for MYQORZO and positive NICE guidance for obstructive hypertrophic cardiomyopathyJul 31, 2026
- Cytokinetics reported positive topline results from the Phase 3 ACACIA-HCM trial of aficamtenMay 5, 2026
- Cytokinetics received European Commission approval for MYQORZO to treat symptomatic obstructive hypertrophic cardiomyopathy in adultsFeb 17, 2026
- Cytokinetics launched MYQORZO (aficamten) in U.S. for obstructive cardiomyopathyJan 27, 2026